KRAS and adenocarcinoma: A study of 102 cases of LCLC revealed that adenocarcinoma-associated mutations (EGFR, KRAS, BRAF, and ALK) occurred exclusively in the null immunophenotype or adenocarcinoma-differentiated LCLC.